Experience
Valeant Pharmaceuticals NA, LLC
Zydus Pharmaceuticals, Inc.
Secured a permanent injunction against generic defendant on behalf of Valeant in Hatch-Waxman patent infringement litigation concerning an ANDA for generic versions of Cardizem® LA.
Valeant Pharmaceuticals NA, LLC v. Zydus Pharmaceuticals, Inc., 3:17-cv-00449, D.N.J., Judges Sheridan, Goodman
Valeant Pharmaceuticals Int’l, Inc. v. Mylan Pharmaceuticals, Inc.
Valeant; Salix; Progenics
Valeant Pharmaceuticals North America, LLC v. Actavis, Inc.
Valeant Pharmaceuticals North America, LLC
Medicis Pharmaceutical Corp. v. Zydus Pharmaceuticals (USA) Inc.
Medicis Pharmaceutical Corp.
Valeant Pharm. N. Am. LLC and Kaken Pharm. Co. Ltd. v. Zydus Pharm. (USA) Inc.
Kaken Pharmaceutical Co., Ltd.
Finnegan secures 10 years of patent protection for Relistor®
Valeant; Salix; Progenics
Dow Pharmaceutical Sciences, Inc. v. Taro Pharmaceuticals U.S.A., Inc.
Dow Pharmaceutical Sciences, Inc.; Valeant
Otsuka Pharmaceutical Co., Ltd. v. Teva Pharmaceuticals USA, Inc.
Otsuka Pharmaceutical Co.
Elan Pharmaceuticals, Inc. v. Ivax Pharmaceuticals, Inc.
Elan Pharmaceuticals, Inc.
Cephalon, Inc. v. Sun Pharmaceuticals Industries, Inc.
Cephalon, Inc.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.